ESR1 and in situ carcinoma: The risk varies according to route of delivery and MHT type (vaginal vs. systemic estrogen replacement, estrogen-only vs. combined MHT regimens, body-identical vs. synthetic hormones), and breast cancer type (carcinoma in situ vs. estrogen receptor negative vs. estrogen receptor positive invasive breast cancer, tumor grade and stage).